Unknown

Dataset Information

0

Radiofrequency ablation of stage IA non-small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial.


ABSTRACT: BACKGROUND:A prospective multicenter phase II trial to evaluate the survival outcomes of percutaneous radiofrequency ablation (RFA) for patients with stage IA non-small cell lung cancer (NSCLC), ineligible for surgery. METHODS:Patients with a biopsy-proven stage IA NSCLC, staging established by a positron emission tomography-computed tomography (PET-CT), were eligible. The primary objective was to evaluate the local control of RFA at 1-year. Secondary objectives were 1- and 3-year overall survival (OS), 3-year local control, lung function (prior to and 3 months after RFA) and quality of life (prior to and 1 month after RFA). RESULTS:Of the 42 patients (mean age 71.7 y) that were enrolled at six French cancer centers, 32 were eligible and assessable. Twenty-seven patients did not recur at 1 year corresponding to a local control rate of 84.38% (95% CI, [67.21-95.72]). The local control rate at 3 years was 81.25% (95% CI, [54.35-95.95]). The OS rate was 91.67% (95% CI, [77.53-98.25]) at 1 year and 58.33% (95% CI, [40.76-74.49]) at 3 years. The forced expiratory volume was stable in most patients apart from two, in whom we observed a 10% decrease. There was no significant change in the global health status or in the quality of life following RFA. CONCLUSION:RFA is an efficient treatment for medically inoperable stage IA NSCLC patients. RFA is well tolerated, does not adversely affect pulmonary function and the 3-year OS rate is comparable to that of stereotactic body radiotherapy, in similar patients. TRIAL REGISTRATION:ClinicalTrials.gov Identifier NCT01841060 registered in November 2008.

SUBMITTER: Palussiere J 

PROVIDER: S-EPMC6109264 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Radiofrequency ablation of stage IA non-small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial.

Palussière J J   Chomy F F   Savina M M   Deschamps F F   Gaubert J Y JY   Renault A A   Bonnefoy O O   Laurent F F   Meunier C C   Bellera C C   Mathoulin-Pelissier S S   de Baere T T  

Journal of cardiothoracic surgery 20180824 1


<h4>Background</h4>A prospective multicenter phase II trial to evaluate the survival outcomes of percutaneous radiofrequency ablation (RFA) for patients with stage IA non-small cell lung cancer (NSCLC), ineligible for surgery.<h4>Methods</h4>Patients with a biopsy-proven stage IA NSCLC, staging established by a positron emission tomography-computed tomography (PET-CT), were eligible. The primary objective was to evaluate the local control of RFA at 1-year. Secondary objectives were 1- and 3-year  ...[more]

Similar Datasets

| S-EPMC4035627 | biostudies-literature
| S-EPMC8040894 | biostudies-literature
| S-EPMC5573330 | biostudies-literature
| S-EPMC8782025 | biostudies-literature
| S-EPMC8451775 | biostudies-literature
| S-EPMC8383082 | biostudies-literature
| S-EPMC3115473 | biostudies-literature
| S-EPMC7143923 | biostudies-literature
| S-EPMC7550467 | biostudies-literature
| S-EPMC5992954 | biostudies-literature